If you're looking to put your money to work by investing in the share market next year, then you might want to take a look at the shares listed below.
Here's why they are currently rated as buys:
a2 Milk Company Ltd (ASX: A2M)
a2 Milk Company is a leading fresh milk and infant formula company. While FY 2021 is going to be a disappointing year because of the pandemic's impact on the daigou channel, management appears confident that these are only temporary headwinds and that its growth will resume in FY 2022. One broker that appears to believe the recent weakness in the a2 Milk share price is a buying opportunity is Morgans. It has recently retained its add rating and put a $12.20 price target on the company's shares.
Pro Medicus Limited (ASX: PME)
Pro Medicus is healthcare technology company that provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions to healthcare organisations across the globe. Due to the quality of its software and its sizeable market opportunity, Pro Medicus has a lot of admirers. One of those is Morgans. Last week the broker retained its add rating and lifted its price target on the company's shares to $35.02. This was in response to the signing of a five-year contract with MedStar Health worth a total of A$18 million.
Whispir Ltd (ASX: WSP)
Whispir is a software-as-a-service communications workflow platform provider. Its industry-leading software platform allows users to deliver actionable two-way interactions at scale using automated multi-channel communication workflows. Management estimates that the Workflow Communications platform as a Service market could be worth US$8 billion per year by 2024. Analysts at Ord Minnett currently have a $4.40 price target on the company's shares. This compares to the current Whispir share price of $3.22.
